Bionano Genomics (BNGO) investor relations material

Executive summary

• Q1 2026 revenue reached $6.7 million, up 4% year-over-year, with 8,178 flow cells sold, a 17% increase from Q1 2025, and strong consumables growth supporting strategic priorities.

• Gross margin improved to 49% from 46% in Q1 2025, with adjusted gross margin also at 49%.

• Net loss widened to $8.3 million from $3.1 million in Q1 2025, reflecting increased R&D expenses and lower other income.

• Cash, cash equivalents, and available-for-sale securities totaled $24.7 million as of March 31, 2026, with $10.3 million subject to restrictions.

• Business momentum supported by new CPT codes, increased reimbursement rates, and expanding clinical evidence for OGM.

Financial highlights

• Product revenue reached $6.1 million, consumables revenue grew 20% year-over-year to $3.9 million, and instrument revenue rose 40% to $1.0 million.

• Sold 8,178 flow cells in Q1, a record for any Q1.

• Adjusted gross margin and GAAP gross margin both at 49%.

• Adjusted operating expense was $9.1 million, up from $8.5 million in Q1 2025.

• Cash and cash equivalents at quarter-end were $3.4 million, with $11.0 million in short-term investments and $10.3 million in restricted cash/investments.

Outlook and guidance

• Full-year 2026 revenue guidance reaffirmed at $30–33 million, with Q2 2026 revenue guidance of $7.5–7.8 million.

• Cash runway expected to extend into 2027.

• Not expecting to reach cash flow break even by end of 2026; targeting significant burn reduction by Q4 2027.

• Management expects continued operating losses and negative cash flows for at least the next year.

• Additional capital is required in the near term to fund operations; failure to secure funding may result in curtailment or cessation of operations.